Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/1/2020
SIETES contiene 92882 citas

 
 
 1 a 20 de 3432 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J, et al.. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet 2020;395:4 de enero. [Ref.ID 103501]
2. Cita con resumen
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. . Ann Intern Med 2019;171:248-56. [Ref.ID 103236]
3. Cita con resumen
Taylor P. FDA grants surprise OK to Sarepta’s DMD therapy after earlier rejection. PMLiVE 2019:13 de diciembre. [Ref.ID 103233]
4. Cita con resumen

Se ha producido un error durante la generación de la página

. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:1705-11. [Ref.ID 103213]
5. Cita con resumen
Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. International Journal of Medical Sciences 2019;16:julio. [Ref.ID 103207]
7.Enlace a cita original Cita con resumen
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med 2019:30 de julio. [Ref.ID 103183]
8.Enlace a cita original Cita con resumen
Walsh LK, Donelle J, Dodds L, Hawken S, Wilson K, Benchimol EI, Chakraborty P, Guttmann A, Kwong JC, MacDonald NE, Sprague AE, Top KA, Walker MC, Web SW, Fell DB. Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study. BMJ 2019;366:10 de julio. [Ref.ID 103171]
10. Cita con resumen
van Eijk AM, Zulaika G, Lenchner M, Mason L, Sivakami M, Nyothach E, Unger H, Laserson KFPhillips-Howard PA. Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis. The Lancet Public Health 2019;4:1. [Ref.ID 103161]
11.Enlace a cita original Cita con resumen
Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, Jackson L, Keogh M, Lawrence T, Montgomery AA, Roberts TE, Sprange K, Tan W, Thandi S, Wilson J, Duley L, on behalf of the G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet 2019:2 de mayo. [Ref.ID 103140]
12.Enlace a cita original Cita con resumen
Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019;365:9 de abril. [Ref.ID 103085]
13. Cita con resumen
Samper E. El doble filo del ibuprofeno y otros antiinflamatorios . eldiario.es 2019:22 de abril. [Ref.ID 103079]
14. Cita con resumen
Taylor P. GSK, J&J say monthly injection keeps HIV controlled. PMLiVE 2019:8 de marzo. [Ref.ID 103051]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Chambers HF. Omadacycline — The newest tetracycline. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103037]
17.Enlace a cita originalTiene citas relacionadas Cita con resumen
O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103036]
18.Enlace a cita originalTiene citas relacionadas Cita con resumen
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103035]
19. Cita con resumen
Taylor P. Finch’s microbiota drug for C. diff gets FDA breakthrough status. PMLiVE 2019:11 de febrero. [Ref.ID 103019]
20.Enlace a cita original Cita con resumen
Modin D, Jorgensen ME, Gislason S, Jensen JS, Kober L, Claggett B, Hegde SM, Solomon SD, Torp-Pedersen C, Biering-Sorensen T. Influenza vaccine in heart failure cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. Circulation 2018;139:10 de diciembre. [Ref.ID 102908]
Seleccionar todas
 
 1 a 20 de 3432 siguiente >>